Why Monitor Organs with Lurbinectedin?
Lurbinectedin (Zepzelca), used for small cell lung cancer, requires organ monitoring due to risks of myelosuppression, hepatotoxicity, and other effects. Guidelines from prescribing information emphasize baseline and periodic tests.[1]
Liver Function Tests
Check liver enzymes (ALT, AST, bilirubin) before each cycle. Hold or reduce dose if grade 3/4 elevations occur; permanent discontinuation needed for persistent severe cases. Hepatotoxicity is common, affecting up to 10% of patients.[1][2]
Bone Marrow and Blood Counts
Monitor complete blood counts (CBC) weekly during the first two cycles, then before each dose. Neutropenia (grade 3/4 in 50%+ patients), thrombocytopenia, and anemia are frequent; delays or reductions prevent complications like infection or bleeding.[1]
Kidney Function
Assess creatinine clearance or serum creatinine before dosing, especially in patients with baseline impairment. Dose adjustments apply if clearance falls below 30 mL/min; rhabdomyolysis risk adds caution.[1]
Heart Monitoring
Obtain ECGs for patients with heart failure history or QT prolongation risk. Lurbinectedin can cause QTc prolongation; avoid in those with relevant cardiac issues.[1]
Other Considerations
- Pregnancy testing: Required before starting in females of reproductive potential due to embryo-fetal toxicity.
- No routine lung monitoring specified beyond general SCLC context.
- Frequency: Baseline, then per-cycle for most tests.
Patients should report fatigue, bruising, jaundice, or infections promptly. Consult oncology guidelines for full protocols.
[1]: Zepzelca Prescribing Information, Jazz Pharmaceuticals (https://www.zepzelca.com/)
[2]: DrugPatentWatch.com, Lurbinectedin Safety Profile (https://www.drugpatentwatch.com/p/tradename/ZEPZELCA)